



## LIST OF TABLES

Table No.	TITLE	Page No.
3.1	Calibration Curve of DTX in DTX in ACN: water (70:30) mobile phase at $\lambda_{\max} = 230\text{nm}$	78
3.2	Accuracy of DTX measurement using ACN: water (70:30) mobile phase at $\lambda_{\max}=230\text{nm}$ .	79
3.3	Precision of DTX measurement using ACN: water (70:30) mobile phase at $\lambda_{\max}=230\text{nm}$	80
3.4	Accuracy of DTX measurement in PLGA formulation using ACN: water (70:30) mobile phase at $\lambda_{\max}=230\text{nm}$	80
3.5	Calibration of AppI using standard known concentration in MCF7 cell line	87
3.6	Calibration of IPP using standard known concentration in MCF7 cell line	88
3.7	Calibration of IPP using standard known concentration in BO2 cell line	89
3.8	Accuracy and precision for inter and intraday measurement of IPP.	91
3.9	Accuracy and precision for inter and intraday measurement of AppI.	91
3.10	Calibration Curve of coumarin-6 ( $\lambda_{\text{excitation}} = 430\text{nm}$ ; $\lambda_{\text{emission}} = 485 \text{ nm}$ )	93
3.11	Accuracy coumarin-6 measurement in PLGA formulation using ACN ( $\lambda_{\text{ex}} = 430\text{nm}$ ; $\lambda_{\text{em}} = 485 \text{ nm}$ )	94
3.12	Accuracy of coumarin-6 measurement in PBCA formulation using ACN mobile phase at $\lambda_{\max}=230\text{nm}$	95
3.13	Calibration of poloxamer P188 in DCM : phosphate buffer (pH 7.4) at 510 nm	96
3.14	Accuracy of poloxamer in presence of PLGA NP at 510 nm	97
3.15	Accuracy of poloxamer in presence of PBCA NP at 510 nm	97
3.16	Calibration of PEG in of I2/KI solution at 500 nm	98
3.17	Accuracy of PEG determination in presence of PLGA NP at 500 nm	99
3.18	Accuracy of PEG determination in presence of PBCA NP at 500 nm	100
3.19	Calibration Curve of ZOL in mobile phase (2.5 L water, 4.7 mL formic acid, pH 3.5) at $\lambda_{\max} = 210 \text{ nm}$	101
3.20	Accuracy of Zoledronic acid determination in presence of PLGA NP at 510 nm	102
3.21	Accuracy of Zoledronic acid determination in presence of PBCA NP at 510 nm	103
4.1	Selection of surfactant on particle size and reconstitution property	115
4.2	Effect of surfactant concentration on particle size, zeta potential and % entrapment efficiency	117
4.3	Effect of organic to aqueous ratio on particle size and entrapment efficiency	117

4.4	Effect of PLGA concentration on particle size and % entrapment	118
4.5	Estimation of PEG content in formulation	119
4.6	Estimation of poloxamer P188 in formulation	119
4.7	Physicochemical characterization of PLGA NP, PEGylated PLGA NP and ZOL conjugated PEGylated PLGA NP	120
4.8	Particle size and % drug entrapment of 6-coumarin loaded PLGA NP formulations	122
4.9	Effect of different cryoprotectants on the particle size and redispersion	130
4.10	Stability data for ZOL conjugated DTX loaded PLGA-PEG NPs	132
4.11	Effect of surfactant concentration on nanoparticle morphology and drug entrapment	148
4.12	Effect of monomer concentration on entrapment efficiency, particle size and zeta potential	149
4.13	Effect of monomer concentration on entrapment efficiency, particle size and zeta potential	154
4.14	Characterization of Prepared PBCA NP formulations	154
4.15	Particle size and % drug entrapment of 6-coumarin loaded PBCA NP formulations	161
4.16	Amount of residual poloxamer P188 in PBCA NP formulations	161
4.17	Effect of different cryo-protectant on particle size and reconstitution property	165
4.18	Stability data for DTX loaded PBCA based NP formulations	166
5.1	Phagocytic uptake of 6-coumarin loaded PEGylated PLGA NP formulations by mouse macrophage cell line RAW264 after incubation for 60, 120 and 240 min using FACS as estimation technique	178
5.2	Phagocytic uptake of 6-coumarin loaded PEGylated PBCA NP formulations by mouse macrophage cell line RAW264 after incubation for 60, 120 and 240 min using FACS as estimation technique.	180
5.3	Endocytic uptake of 6-coumarin loaded PLGA-PEG20 NP and PLGA-PEG-ZOL NP in human breast cancer cell line (a) MCF7 and (b) BO2 after incubation for 30, 60 and 120 min using FACS as estimation technique.	185
5.4	Endocytic uptake of 6-coumarin loaded PBCA-PEG20 NP and PBCA-PEG-ZOL NP in human breast cancer cell line (a) MCF7 and (b) BO2 after incubation for 30, 60 and 120 min using FACS as estimation technique.	187
5.5	Inhibitors of cellular uptake of NP and its concentration used for cell culture.	193
5.6	Characterization of route for NP uptake using various endocytosis inhibitors on BO2 cell line and 6-coumarin loaded PLGA-PEG-20 NP and PLGA-PEG-ZOL NP.	193
5.7	Characterization of route for NP uptake using various endocytosis inhibitors on BO2 cell line and 6-coumarin	195

5.8	loaded PBCA-PEG-20 NP and PBCA-PEG-ZOL NP. PLGA-PEG20 NP and PLGA-PEG-ZOL NP retention time in intracellular compartment after uptake in BO2 cell line after incubation for control, 60, 120 and 240 min using FACS as estimation technique.	200
5.9	PBCA-PEG20 NP and PBCA-PEG-ZOL NP retention time in intracellular compartment after uptake in BO2 cell line after incubation for control, 60, 120 and 240 min using FACS as estimation technique.	201
5.10	Cytotoxicity study of DTX solution, ZOL-DTX solution, DTX loaded PLGA-PEG20 NP and PLGA-PEG-ZOL NP in MCF7 after 48 h using MTT assay.	204
5.11	Cytotoxicity study of DTX solution, ZOL-DTX solution, DTX loaded PLGA-PEG20 NP and PLGA-PEG-ZOL NP in MCF7 after 72 h using MTT assay.	205
5.12	Cytotoxicity study of DTX solution, ZOL-DTX solution, DTX loaded PLGA-PEG20 NP and PLGA-PEG-ZOL NP in BO2 cell line after 48 h using MTT assay.	205
5.13	Cytotoxicity study of DTX solution, ZOL-DTX solution, DTX loaded PLGA-PEG20 NP and PLGA-PEG-ZOL NP in BO2 cell line after 72 h using MTT assay.	206
5.14	Cytotoxicity study of DTX solution, ZOL-DTX solution, DTX loaded PLGA-PEG20 NP and PLGA-PEG-ZOL NP in MCF7 and BO2 cell line after 48 h and 72 h using MTT assay.	207
5.15	Cytotoxicity study of DTX solution, ZOL-DTX solution, DTX loaded PBCA-PEG20 NP and PBCA-PEG-ZOL NP in MCF7 after 48 h using MTT assay.	211
5.16	Cytotoxicity study of DTX solution, ZOL-DTX solution, DTX loaded PBCA-PEG20 NP and PBCA-PEG-ZOL NP in MCF7 after 72 h using MTT assay.	212
5.17	Cytotoxicity study of DTX solution, ZOL-DTX solution, DTX loaded PBCA-PEG20 NP and PBCA-PEG-ZOL NP in BO2 after 48 h using MTT assay.	212
5.18	Cytotoxicity study of DTX solution, ZOL-DTX solution, DTX loaded PBCA-PEG20 NP and PBCA-PEG-ZOL NP in BO2 after 72 h using MTT assay.	213
5.19	Cytotoxicity study of DTX solution, ZOL-DTX solution, DTX loaded PBCA-PEG20 NP and PBCA-PEG-ZOL NP in MCF7 and BO2 cell line after 48 h and 72 h using MTT assay.	214
5.20	Apoptosis estimation in MCF7 and BO2 cell lines after treatment of Control (PBS), DTX solution, DTX loaded PLGA-PEG20 NP and PLGA-PEG-ZOL NP by Annexin V- FITC & PI staining using FACS technique.	224
5.21	AppI accumulation after treatment with ZOL solution and PLGA-PEG-ZOL NP along with control (PBS) in MCF7 cell line.	232
5.22	IPP accumulation after treatment with ZOL solution and PLGA-PEG-ZOL NP along with control (PBS) in MCF7 cell	233

---

	line.	
5.23	IPP and ApppI accumulation after treatment with ZOL solution and PLGA-PEG-ZOL NP along with control (PBS). IPP and ApppI in MCF7 cell line and IPP in BO2 cell line.	233
5.24	IPP accumulation after treatment with ZOL solution and PLGA-PEG-ZOL NP along with control (PBS) in BO2 cell line.	234
5.25	IPP accumulation after treatment with ZOL solution and PLGA-PEG-ZOL NP along with control (PBS) in BO2 cell line.	234
6.1	Effect of quantity of SnCl <sub>2</sub> on radiolabeling of DTX, PLGA NP and PBCA NP formulations	246
6.2	In vitro stability of radiolabeled DTX, PLGA NP and PBCA NP formulations	246
6.3	Effect of DTPA on radiolabeling of DTX, PLGA NP and PBCA NP formulations	247
6.4	Biodistribution of <sup>99m</sup> Tc labeled DTX and PLGA NPs and the radioactivity was measured after (a) 1 h, (b) 4 h and (c) 24 h post injection.	248
6.5	Biodistribution of <sup>99m</sup> Tc labeled DTX and PBCA NPs and the radioactivity was measured after (a) 1 h, (b) 4 h and (c) 24 h post injection.	249
6.6	Biodistribution of PLGA NP formulations by measuring radioactivity ( <sup>99m</sup> Tc-NP complex).	253
6.7	Biodistribution of PBCA formulations by measuring radioactivity ( <sup>99m</sup> Tc-NP complex).	256